AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method of ~~A pharmaceutical composition for~~ improving at least one symptom resulting from a tumor cell in a patient in need thereof, comprising administering to the patient a compound of ~~represented by~~ the ~~following general~~ formula (1) or a pharmacologically acceptable salt thereof: ~~as an active ingredient.~~



(1)

wherein R^1 represents a hydrogen atom or a C2-4 alkanoyl group and R^2 represents a group represented by the following ~~formulae~~ formula (A), (B), ~~(C),~~ (D), (E), (F) or (G):



wherein R^3 represents a C1-4 alkyl group.

2. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, comprising improving at least one symptom by apoptosis of the tumor cell.

3. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, comprising improving at least one symptom resulting from the tumor cell without the contribution of apoptosis of the tumor cell.

4. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, comprising improving at least one symptom resulting from the tumor cell by inhibiting activation of NF-κB.

5. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, wherein the symptom is a tumor metastasis.

6. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 5, comprising improving the tumor metastasis by inhibiting adhesion to a vascular endothelial cell.

7. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, comprising improving at least one symptom resulting from the tumor cell by inhibiting proliferation of the tumor cell.

8. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, wherein the symptom is one selected from the group consisting of Hodgkin's disease, cancer cachexia, and leukemia.

9. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, wherein the tumor cell is a breast cancer cell.

10. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, wherein the composition is represented by the following formula (1a) or (1b):[[.]]



(1a)



(1b)

11. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 8, comprising improving at least one symptom among loss of body weight, a decrease in hematocrit, a decrease in fat, and a decrease in muscle, which are the symptoms of cancer cachexia.

12. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 3, comprising improving at least one symptom resulting from the tumor cell by inhibiting intratumoral angiogenesis formed by the tumor cell.

13. (Currently Amended) A method ~~pharmaceutical composition comprising as an active ingredient a compound, represented by the following general formula (1), which is capable~~ of enhancing the effect of a therapy ~~by inhibiting activation of NF-κB caused by the therapy~~ that causes the activation of NF-κB in a patient treated by the therapy, ~~or a pharmacologically acceptable salt thereof.~~ comprising administering to the patient a composition comprising a compound of formula (1) or a pharmacologically acceptable salt thereof:



(1)

wherein R^1 represents a hydrogen atom or a C2-4 alkanoyl group and R^2 represents a group represented by the following ~~formulae~~ formula (A), (B), (C), (D), (E), (F) or (G):



(A)



(B)



(C)



(D)



(E)



(F)



(G)

wherein R^3 represents a C1-4 alkyl group.

14. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 13, wherein the therapy that activates NF-κB is a therapy using an antitumor agent.

15. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 13, wherein the therapy that activates NF-κB is radiotherapy for a tumor cell.

16. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 14, comprising the antitumor agent as an active ingredient.

17. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 14, wherein the antitumor agent is camptothecin or daunorubicin.

18. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 13, wherein the compound is represented by the following formula (1a) or (1b):[[.]]



(1a)



(1b)

19. (Currently Amended) A method of ~~tumor cell proliferation inhibitor for~~ inhibiting proliferation of a tumor cell in a cancer patient comprising administering to the patient a compound of ~~represented by~~ the ~~following general~~ formula (1) or a pharmacologically acceptable salt thereof ~~as an active ingredient.~~:



(1)

wherein R^1 represents a hydrogen atom or a C2-4 alkanoyl group and R^2 represents a group represented by the following ~~formulae~~ formula (A), (B), ~~(C),~~ (D), (E), (F) or (G):



(A)



(B)



(D)



(E)



(F)



(G)

wherein R^3 represents a C1-4 alkyl group.

20. (Currently Amended) The method ~~tumor cell proliferation inhibitor~~ of claim 3, wherein the composition is represented by the following formula (1a) or (1b):[[.]]



(1a)



(1b)

21. (Currently Amended) A method of ~~An adhesion molecule expression inhibitor for~~ suppressing the expression of an adhesion molecule in a vascular endothelial cell, comprising administering to the cell a compound of ~~represented by~~ the ~~following general~~ formula (1) or a pharmacologically acceptable salt thereof: ~~as an active ingredient.~~



(1)

wherein R^1 represents a hydrogen atom or a C2-4 alkanoyl group and R^2 represents a group represented by the following formulae (A), (B), (C), (D), (E), (F) or (G):


(A)


(B)


(C)


(D)


(E)


(F)


(G)

wherein R^3 represents a C1-4 alkyl group.

22. (Currently Amended) The method of claim 21~~adhesion molecule expression inhibitor derived from a vascular endothelial cell~~, wherein the composition is the following formula (1a) or (1b):[[.]]


(1a)


(1b)

23. (Currently Amended) A method of ~~An apoptosis inducer for~~ inducing apoptosis of a tumor cell, comprising administering to the cell a compound of ~~represented by~~ the ~~following general~~ formula (1) or a pharmacologically acceptable salt thereof ~~as an active ingredient.~~:



(1)

wherein R^1 represents a hydrogen atom or a C2-4 alkanoyl group and R^2 represents a group represented by the following ~~formulae~~ formula (A), (B), ~~(C),~~ (D), (E), (F) or (G):



(A)



(B)



(D)



(E)



(F)



(G)

wherein R^3 represents a C1-4 alkyl group.

24. (Currently Amended) The method of claim 23 ~~An apoptosis inducer~~, wherein the composition is represented by the following formula (1a) or (1b):[[.]]



(1a)



(1b)

25. (Currently Amended) A method of improving or inhibiting ~~Preventive and therapeutic agents for~~ arteriosclerosis in a patient in need thereof, comprising administering to the patient a compound having NF-κB-inhibitory effect ~~as an active ingredient~~.

26. (Currently Amended) The method ~~preventive and therapeutic agents~~ of claim 25, wherein the compound having NF-κB inhibitory effect is represented by the ~~following general~~ formula (1) or a pharmacologically acceptable salt thereof:[[.]]



(1)

wherein R^1 represents a hydrogen atom or a C2-4 alkanoyl group and R^2 represents a group represented by the following ~~formulae~~ formula (A), (B), (C), (D), (E), (F) or (G):


(A)


(B)


(C)


(D)


(E)


(F)


(G)

wherein R^3 represents a C1-4 alkyl group.

27-28. (Canceled)

29. (Currently Amended) ~~The preventive and therapeutic agents of claim 27, which is are used for~~ A method of preventing or inhibiting ~~repressing~~ cancer metastasis, comprising administering to a cancer patient a compound having NF-κB inhibitory effect.

30. (Currently Amended) A method of alleviating or inhibiting ~~therapeutic agent for~~ cachexia in a patient in need thereof, comprising administering to the patient a compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient:[[.]]



(1)

wherein R^1 represents a hydrogen atom or a C2-4 alkanoyl group and R^2 represents a group represented by the following ~~formulae~~ formula (A), (B), (C), (D), (E), (F) or (G):



(A)



(B)



(C)



(D)



(E)



(F)



(G)

wherein R^3 represents a C1-4 alkyl group.

31. (Currently Amended) The method ~~therapeutic agent for cachexia~~ of claim 30, wherein the composition is represented by the following formula (1a) or (1b):[[.]]



(1a)



(1b)

32. (Currently Amended) The method ~~therapeutic agent for cachexia~~ of claim 30, wherein the patient is a cancer patient~~which is a therapeutic agent for cancer cachexia in a tumor patient~~.

33. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 30, comprising improving at least one symptom among loss of body weight, a decrease in hematocrit, a decrease in fat, and a decrease in muscle, which are the symptoms of the cancer cachexia.

34. (Currently Amended) A method of alleviating or inhibiting ~~therapeutic agent for~~ cachexia in a patient in need thereof, comprising administering to the patient a compound having NF-κB-inhibitory effect ~~as an active ingredient~~.

35-46. (Canceled)